{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:37:10Z","timestamp":1795012630317,"version":"4.9.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The US Food and Drug Administration (FDA)\u2019s authorization of etranacogene dezaparvovec (Hemgenix) is a significant milestone, constituting not only the first FDA approval of a gene therapy for hemophilia but also the first approval of a liver-targeted adeno-associated virus vector gene therapy. This review summarizes the nonclinical studies and clinical development that supported regulatory clearance. Similar to other gene therapies for single gene disorders, both the short-term safety and the phenotypic improvement were unequivocal, justifying the modest-sized safety and efficacy database, which included 57 participants across the phase 2b (3 participants) and phase 3 (54 participants) studies. The most common adverse reactions included liver enzyme elevation, headache, flu-like symptoms, infusion-related reactions, creatine kinase elevation, malaise, and fatigue; these were mostly transient. One participant had hepatocellular carcinoma on a study-mandated liver ultrasound conducted 1 year after vector infusion; molecular analysis of the resected tumor showed no evidence of vector-related insertional mutagenesis as the etiology. A remarkable 96% of participants in the phase 3 trial were able to stop factor IX (FIX) prophylaxis, with the study demonstrating noninferiority to FIX prophylaxis in terms of the primary end point, annualized bleeding rate. Key secondary end points such as the annualized infusion rate, which declined by 97%, and the plasma FIX activity level at 18\u00a0months after infusion, with least squares mean increase of 34.3 percentage points compared with baseline, were both clinically and statistically significant. The FDA\u2019s landmark approval of Hemgenix as a pioneering treatment for hemophilia stands on the shoulders of &amp;gt;20 years of gene therapy clinical research and heralds a promising future for genomic medicines.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010511","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T13:55:00Z","timestamp":1712325300000},"page":"1796-1803","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":51,"title":["Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec"],"prefix":"10.1182","volume":"8","author":[{"given":"Xavier M.","family":"Anguela","sequence":"first","affiliation":[{"name":"1Estuary Biotherapeutics, Inc, Menlo Park, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"High","sequence":"additional","affiliation":[{"name":"2Rockefeller University, New York, NY"},{"name":"3Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"issue":"3","key":"2024040915302211300_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"issue":"6","key":"2024040915302211300_bib2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ymthe.2004.12.022","article-title":"Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models","volume":"11","author":"Davidoff","year":"2005","journal-title":"Mol Ther"},{"issue":"7","key":"2024040915302211300_bib3","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2024040915302211300_bib4","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol Ther"},{"issue":"17","key":"2024040915302211300_bib5","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024040915302211300_bib6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"2024040915302211300_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.omtm.2019.09.005","article-title":"Enhanced factor IX activity following administration of AAV5-R338L \"Padua\" factor IX versus AAV5 WT human factor IX in NHPs","volume":"15","author":"Spronck","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"25","key":"2024040915302211300_bib8","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector\u2013mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2024040915302211300_bib9","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024040915302211300_bib10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/hematology.2022000388","article-title":"Gene therapy for hemophilia","volume":"2022","author":"Nathwani","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"2024040915302211300_bib11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"21","key":"2024040915302211300_bib17","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2024040915302211300_bib12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"issue":"4","key":"2024040915302211300_bib13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/hum.2006.17.440","article-title":"Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors","volume":"17","author":"Halbert","year":"2006","journal-title":"Hum Gene Ther"},{"issue":"23","key":"2024040915302211300_bib14","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2024040915302211300_bib15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2024040915302211300_bib16","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2352-3026(22)00178-8","article-title":"Factor IX Padua for haemophilia B gene addition: universal adaptation and repeated success","volume":"9","author":"George","year":"2022","journal-title":"Lancet Haematol"},{"key":"2024040915302211300_bib18","unstructured":"Summary basis for regulatory action - HEMGENIX. Accessed 22 February 2024. https:\/\/www.fda.gov\/media\/164094\/download?attachment."},{"issue":"19","key":"2024040915302211300_bib19","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2024040915302211300_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1\u20132 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2024040915302211300_bib21","unstructured":"CSL Behring\n              LLC\n            \n          . HEMGENIX (etranacogene dezaparvovec-drlb) [package insert]. U.S. Food and Drug Administration website. Accessed 28 January 2024. https:\/\/www.fda.gov\/media\/163467\/download?attachment.Revised:11\/2022."},{"issue":"17","key":"2024040915302211300_bib22","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","article-title":"Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B","volume":"7","author":"Schmidt","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2024040915302211300_bib23","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"},{"issue":"2","key":"2024040915302211300_bib24","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"2024040915302211300_bib25","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2024040915302211300_bib26","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"2024040915302211300_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024040915302211300_bib28","volume-title":"Proceedings and Abstracts of the 13th Annual Congress of European Association for Haemophilia and Allied Disorders","author":"Majowicz","year":"2020"},{"issue":"11","key":"2024040915302211300_bib29","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A\u00a010 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol Ther"},{"issue":"17","key":"2024040915302211300_bib30","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/bloodadvances.2019000380","article-title":"Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates","volume":"3","author":"Salas","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"2024040915302211300_bib31","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in\u00a0vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"2024040915302211300_bib32","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1006\/mthe.2001.0491","article-title":"Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males","volume":"4","author":"Arruda","year":"2001","journal-title":"Mol Ther"},{"issue":"6","key":"2024040915302211300_bib33","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/mt.2009.56","article-title":"Host and vector-dependent effects on the risk of germline transmission of AAV vectors","volume":"17","author":"Favaro","year":"2009","journal-title":"Mol Ther"},{"issue":"1","key":"2024040915302211300_bib34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","article-title":"Integration of adeno-associated virus (AAV) and recombinant AAV vectors","volume":"38","author":"McCarty","year":"2004","journal-title":"Annu Rev Genet"},{"issue":"3","key":"2024040915302211300_bib35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ng1179","article-title":"AAV serotype 2 vectors preferentially integrate into active genes in mice","volume":"34","author":"Nakai","year":"2003","journal-title":"Nat Genet"},{"issue":"6","key":"2024040915302211300_bib36","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/mt.2012.47","article-title":"Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver","volume":"20","author":"Nowrouzi","year":"2012","journal-title":"Mol Ther"},{"issue":"7","key":"2024040915302211300_bib37","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nm.3230","article-title":"A\u00a0largely random AAV integration profile after LPLD gene therapy","volume":"19","author":"Kaeppel","year":"2013","journal-title":"Nat Med"},{"issue":"7","key":"2024040915302211300_bib38","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ng1380","article-title":"Adeno-associated virus vectors integrate at chromosome breakage sites","volume":"36","author":"Miller","year":"2004","journal-title":"Nat Genet"},{"issue":"8","key":"2024040915302211300_bib39","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus (AAV) integration: an integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol Ther"},{"issue":"6","key":"2024040915302211300_bib40","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/7\/1796\/2220733\/blooda_adv-2023-010511-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/7\/1796\/2220733\/blooda_adv-2023-010511-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T15:30:57Z","timestamp":1712676657000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/7\/1796\/514818\/Hemophilia-B-and-gene-therapy-a-new-chapter-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010511","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]}}}